2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $229.78 million. The enterprise value is $301.48 million.
| Market Cap | 229.78M |
| Enterprise Value | 301.48M |
Important Dates
The next estimated earnings date is Monday, August 12, 2024, before market open.
| Earnings Date | Aug 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 51.41 million shares outstanding. The number of shares has increased by 19.79% in one year.
| Shares Outstanding | 51.41M |
| Shares Change (YoY) | +19.79% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 3.40% |
| Owned by Institutions (%) | 93.57% |
| Float | 49.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.23 |
| Forward PS | 2.29 |
| PB Ratio | 1.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 1.22.
| Current Ratio | 3.52 |
| Quick Ratio | 3.20 |
| Debt / Equity | 1.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.60% and return on invested capital (ROIC) is -52.91%.
| Return on Equity (ROE) | -78.60% |
| Return on Assets (ROA) | -36.90% |
| Return on Capital (ROIC) | -52.91% |
| Revenue Per Employee | $259,858 |
| Profits Per Employee | -$814,679 |
| Employee Count | 274 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.43% in the last 52 weeks. The beta is 1.77, so 2seventy bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | -57.43% |
| 50-Day Moving Average | 4.23 |
| 200-Day Moving Average | 4.10 |
| Relative Strength Index (RSI) | 55.45 |
| Average Volume (20 Days) | 614,965 |
Short Selling Information
The latest short interest is 5.86 million, so 11.40% of the outstanding shares have been sold short.
| Short Interest | 5.86M |
| Short Previous Month | 6.14M |
| Short % of Shares Out | 11.40% |
| Short % of Float | 11.74% |
| Short Ratio (days to cover) | 10.21 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $71.20 million and -$223.22 million in losses. Loss per share was -$4.35.
| Revenue | 71.20M |
| Gross Profit | 55.31M |
| Operating Income | -243.64M |
| Pretax Income | -223.22M |
| Net Income | -223.22M |
| EBITDA | -213.09M |
| EBIT | -223.22M |
| Loss Per Share | -$4.35 |
Balance Sheet
The company has $181.38 million in cash and $253.08 million in debt, giving a net cash position of -$71.70 million or -$1.39 per share.
| Cash & Cash Equivalents | 181.38M |
| Total Debt | 253.08M |
| Net Cash | -71.70M |
| Net Cash Per Share | -$1.39 |
| Equity (Book Value) | 207.44M |
| Book Value Per Share | 4.04 |
| Working Capital | 152.44M |
Cash Flow
In the last 12 months, operating cash flow was -$159.65 million and capital expenditures -$8.22 million, giving a free cash flow of -$167.87 million.
| Operating Cash Flow | -159.65M |
| Capital Expenditures | -8.22M |
| Free Cash Flow | -167.87M |
| FCF Per Share | -$3.22 |
Margins
Gross margin is 77.68%, with operating and profit margins of -342.19% and -313.51%.
| Gross Margin | 77.68% |
| Operating Margin | -342.19% |
| Pretax Margin | -313.51% |
| Profit Margin | -313.51% |
| EBITDA Margin | -299.27% |
| EBIT Margin | -313.51% |
| FCF Margin | -235.77% |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.79% |
| Shareholder Yield | -19.79% |
| Earnings Yield | -97.15% |
| FCF Yield | -73.06% |
Analyst Forecast
The average price target for 2seventy bio is $10.67, which is 138.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.67 |
| Price Target Difference | 138.70% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 12.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -2.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.03 |
| Piotroski F-Score | 2 |